The window Charlotte has been waiting on is almost open.
North Carolina's peptide therapy market has been in a holding pattern that mirrors the broader Southeast. For three years, the most-studied longevity compounds in the clinical literature — sermorelin, CJC-1295, ipamorelin, and the second-generation pineal and copper peptides — have been functionally restricted under FDA Category 2 status. Licensed physicians could still prescribe through 503A compounding pharmacies, but the supply pipeline narrowed. Patients seeking an anti-aging or longevity specalist in Charlotte often heard a version of the same answer: "we are watching the reclassification process."
The pending FDA decision — expected in Q3 2026, never promised on a specific date — is the inflection point. Charlotte's anti-aging and integrative-medicine practices, along with the broader regional endocrnology infrastructure that has built up around the Atrium and Novant systems, have spent the holding period preparing: confirming 503A pharmacy relationships, standardizing baseline-lab protocols, and identifying which patients are candidates and which are not. When supply normalizes, the gap between practices that prepared and practices that did not will be visible in the first three months.
This page is a directory entry, not a sales tool. We maintain the national directory of physicians and 503A compounding pharmacies who can legally prescribe and prepare these compounds. We do not sell peptides. We do not recommend specific products. Our role is to make sure that when Charlotte patients are ready to ask the right questions, the names in front of them are the ones who earned the visit.